Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech, CollabRx Ink Deal to Elucidate MDx Information

NEW YORK (GenomeWeb News) – CollabRx announced after the close of the market Wednesday a development and commercialization partnership pairing its technology and content resources with Life Technologies' cancer diagnostics development and laboratory-developed test services business.

Under the terms of the multi-year deal, Life Tech will use CollabRx's technology and content to elucidate results from its own molecular profiling panels. Content from CollabRx includes clinically relevant knowledge about clinical trials, drugs, biologics and other information that may be useful in deciding a treatment regimen for cancer. CollabRx does not provide specific treatment recommendations, however.

"Molecular analysis, including genetic sequencing, is increasingly becoming an important part of the clinical management of cancer patients," James Karis, Co-CEO of CollabRx, said in a statement. "However, the sheer volume and complexity of genetic data that is being produced, particularly in the course of therapy development, is outpacing the ability of practicing physicians to stay current, and more importantly understand how to apply this genetic data in treating their patients."

CollabRx aggregates and contextualizes "the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts," according to the San Francisco-based company. Life Tech will include this capability with its molecular tests, it said.

"It's critical to contextualize the results of complex cancer panels to make them useful for interpreting and treating physicians," Ronnie Andrews, president of Medical Sciences at Life Tech, said. "CollabRx has pioneered the development of a scalable platform and process to provide actionable, accessible, and credible knowledge at the point of care to aid physicians in developing a cancer treatment plan based on tumor molecular profiles."

Financial and other terms of the deal were not disclosed.

Earlier on Wednesday Ingenuity Systems announced a deal with Life Tech to develop a solution to help physicians interpret information from Life Tech's molecular diagnostic tests.

CollabRx changed its name from Tegal last week following shareholder approval.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.